How should we define disease and outcomes in axial psoriatic arthritis?

Abstract

Axial involvement (inflammation of sacroiliac joints or spine, or both) is reported in 25–70% of patients with psoriatic arthritis. In The Lancet Rheumatology, Philip J Mease and colleagues 1 Mease PJ Helliwell PS Gladman DD et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021; (published online June 29.)https://doi.org/10.1016/S2665-9913(21)00105-3 Summary Full Text Full Text PDF Scopus (12) Google Scholar report data on the efficacy of guselkumab on axial signs and symptoms of psoriatic arthritis. For this pooled analysis, patients with axial involvement defined by local imaging evidence of sacroiliitis from the phase 3 DISCOVER-1 and DISCOVER‑2 trials were selected. The findings showed a substantial improvement in multiple axial outcomes, including the Bath ankylosing spondylitis disease activity index (BASDAI), modified BASDAI (excluding peripheral joint pain), spinal pain, and Ankylosing Spondylitis Disease Activity Score (ASDAS). Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studiesPatients with active psoriatic arthritis and imaging-confirmed sacroiliitis who were treated with guselkumab every 4 weeks or every 8 weeks had greater mean improvements in BASDAI and ASDAS (as early as week 8) than did placebo-treated participants, with sustained improvements at week 52. Full-Text PDF